Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Irish Generics Body Wants “Fundamental” Reform Of Medicines Procurement

Executive Summary

Two generic industry associations have merged to form a single body that includes the largest generic companies in Ireland. Medicines For Ireland has marked its creation by saying it plans to push for a reform of Irish medicines procurement policies, particularly in areas such as tackling drug shortages, and has called for action to promote the use of biosimilars.

You may also be interested in...

Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures

The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.

Irish generics association gets new name

The Association of Pharmaceutical Manufacturers in Ireland (APMI) has been relaunched as the Irish Generic Medicines Association (IGMA), a name that is designed to reflect its specific remit, scope of functions and responsibilities, it announced. The association represents seven companies employing 2,300+ people in Ireland. The member companies are Accord Healthcare, Actavis Ireland, Clonmel Healthcare Ltd, Fannin Ltd, Hospira Ireland, Rowex Ltd and Pinewood Healthcare. The organization's primary purpose is to promote and support the supply of affordable medicines in Ireland, and is the recognized negotiating body on supply and pricing of generics in the country. Among other things, it is calling for new legislation in Ireland on biosimilars and high-tech generic molecules.

UK Prepares For New International Regulatory Reliance Framework

From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts